Calliditas Therapeutics
our lead indication nephropathy significant unmet medical need i | Calliditas Therapeutics
Company
Deck Type
IPO
Sector
Industry
Deck date
June 2020
Slide
8 of 38
Related slides by other companies
AN2 Therapeutics
Investor Presentation
February 2025
disease growing prevalence in the | AN2 Therapeutics
AN2 Therapeutics
Investor Presentation
March 2025
disease growing prevalence in the | AN2 Therapeutics
Immatics
Investor Presentation
November 2023
targeting so | Immatics
RayzeBio
IPO
September 2023
lead clinical indication refractory tumors nets tumors of the tract net and pancreas net have limited als gses | RayzeBio
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights